In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Cipla Medpro Of India Avoids S. Africa Firm’s Takeover Move

This article was originally published in PharmAsia News

Executive Summary

India's Cipla Medpro was saved from a takeover move by a South African drug maker when Cipla's major supplier, Cipla Limited, said it would cancel its agreement if the buyout occurred. Adcock Ingram, South Africa's second-largest pharmaceutical company, had planned to buy Cipla Medpro to increase its share of the generics market. Cipla Limited, rejected the offer, however, causing Adcock to cancel its proposed takeover. The South African firm called for the Johannesburg Stock Exchange to launch an investigation into Cipla Limited's agreements with Cipla Medpro. (Click here for more

You may also be interested in...

US FDA’s 2020 Approvals: A Deep Pipeline, And More Of The Expected

Almost 50 novel agents are already under review at FDA for potential 2020 approval. Candidates are notably diverse, with concentrations in established strongholds (oncology, neuroscience), popular programs (breakthrough), and powerhouse sponsors (keep an eye on Bristol-Myers Squibb right out of the gate).

Gene Therapy Approvals By US FDA Could Double In 2020

CBER is starting the year with four novel gene and cell therapy applications under review and rolling submissions underway for more.

Long Hot Summer For Novel Drug Reviews Forecast At US FDA

Submission surge in late 2019 means a spike in late summer 2020 user fee goals, including 16 novel agents in August alone.




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts